Related Experiment Video
Updated: Jun 21, 2026
08:04
Monitoring Tumor Metastases and Osteolytic Lesions with Bioluminescence and Micro CT Imaging
Published on: April 14, 2011
Tumor-induced osteomalacia: a case report
Daniel Dutra Romualdo-Silva1, Bárbara Campolina Carvalho Silva, Cristiane Vasconcelos Caetano
1Departamento de Doenças Osteometabólicas, Serviço de Endocrinologia, Hospital Santa Casa, Belo Horizonte, MG, Brazil.
Arquivos Brasileiros De Endocrinologia E Metabologia
|July 7, 2009
Summary
Tumor-induced osteomalacia (TIO) is a rare condition caused by tumors overproducing fibroblast growth factor 23. Surgical removal of the tumor resolves TIO, preventing severe disability and death.
Area of Science:
- Endocrinology
- Oncology
- Pathology
Background:
- Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by excessive fibroblast growth factor 23 (FGF23) production.
- This leads to renal phosphate wasting (hyperphosphaturia) and low serum phosphate (hypophosphatemia), with abnormal vitamin D levels.
Observation:
- A case report details a middle-aged male patient presenting with bone pain and profound muscle weakness.
- Diagnostic workup revealed TIO, with the causative tumor identified on his thigh.
Findings:
- Resection of the phosphaturic mesenchymal tumor, mixed connective tissue type, led to complete normalization of biochemical parameters.
- The patient's symptoms resolved following tumor removal.
Implications:
- Early recognition and diagnosis of TIO are crucial for effective management.
- Surgical excision of the responsible tumor is curative, preventing debilitating complications and mortality associated with TIO.
